4.7 Article

Effect of B-Vitamin Therapy on Progression of Diabetic Nephropathy A Randomized Controlled Trial

期刊

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
卷 303, 期 16, 页码 1603-1609

出版社

AMER MEDICAL ASSOC
DOI: 10.1001/jama.2010.490

关键词

-

资金

  1. Pan American Laboratories in the United States
  2. Medice Arzneimittel Putter GmbH Co in Germany
  3. Canadian Institutes of Health Research [MCT-41551]
  4. Kidney Foundation of Canada

向作者/读者索取更多资源

Context Hyperhomocysteinemia is frequently observed in patients with diabetic nephropathy. B-vitamin therapy (folic acid, vitamin B-6, and vitamin B-12) has been shown to lower the plasma concentration of homocysteine. Objective To determine whether B-vitamin therapy can slow progression of diabetic nephropathy and prevent vascular complications. Design, Setting, and Participants A multicenter, randomized, double-blind, placebo-controlled trial (Diabetic Intervention with Vitamins to Improve Nephropathy [DIVINe]) at 5 university medical centers in Canada conducted between May 2001 and July 2007 of 238 participants who had type 1 or 2 diabetes and a clinical diagnosis of diabetic nephropathy. Intervention Single tablet of B vitamins containing folic acid (2.5 mg/d), vitamin B-6 (25 mg/d), and vitamin B-12 (1 mg/d), or matching placebo. Main Outcome Measures Change in radionuclide glomerular filtration rate (GFR) between baseline and 36 months. Secondary outcomes were dialysis and a composite of myocardial infarction, stroke, revascularization, and all-cause mortality. Plasma total homocysteine was also measured. Results The mean (SD) follow-up during the trial was 31.9 (14.4) months. At 36 months, radionuclide GFR decreased by a mean (SE) of 16.5 (1.7) mL/min/1.73 m(2) in the B-vitamin group compared with 10.7 (1.7) mL/min/1.73 m(2) in the placebo group (mean difference, -5.8; 95% confidence interval [CI], -10.6 to -1.1; P=.02). There was no difference in requirement of dialysis (hazard ratio [HR], 1.1; 95% CI, 0.4-2.6; P=.88). The composite outcome occurred more often in the B-vitamin group (HR, 2.0; 95% CI, 1.0-4.0; P=.04). Plasma total homocysteine decreased by a mean (SE) of 2.2 (0.4) mu mol/L at 36 months in the B-vitamin group compared with a mean (SE) increase of 2.6 (0.4) mu mol/L in the placebo group (mean difference, -4.8; 95% CI, -6.1 to -3.7; P<.001, in favor of B vitamins). Conclusion Among patients with diabetic nephropathy, high doses of B vitamins compared with placebo resulted in a greater decrease in GFR and an increase in vascular events.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据